Current Problems in Cardiology
Volume 34, Issue 2 , Pages 51-84, February 2009

Aldosterone and Cardiovascular Disease

Abstract 

Aldosterone is an adrenal hormone that regulates sodium, fluid, and potassium balance. Jerome Conn first described the syndrome of autonomous and excessive aldosterone secretion or “primary aldosteronism.” Contrary to the historical belief, recent studies indicate that primary aldosteronism is a common cause of hypertension with a prevalence of 5-10% among general hypertensive patients. Various animal models have demonstrated that aldosterone in association with a high salt diet results in target-organ inflammation and fibrosis. Similarly, cross-sectional and observational human studies have demonstrated the association of aldosterone with development and severity of hypertension, congestive heart failure, coronary artery disease, chronic kidney disease, and metabolic syndrome. Several interventional studies have also demonstrated the beneficial effects of mineralocorticoid receptor antagonists in these disease processes, particularly hypertension, heart failure, and post myocardial infarction, further supporting the role of aldosterone in their pathogenesis. We review the role of aldosterone in these various cardiovascular disease processes along with potential mechanisms and treatment.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Drs. Krishna K. Gaddam, Eduardo Pimenta, and Saima Husain have no conflicts of interest to disclose. Dr. David A. Calhoun is Consultant to Astra Zeneca, CV Therapeutics, and Novartis.

PII: S0146-2806(08)00166-7

doi:10.1016/j.cpcardiol.2008.10.002

Current Problems in Cardiology
Volume 34, Issue 2 , Pages 51-84, February 2009